ABSTRACT GABA A receptors in cerebellar granule cells are unique in expressing a subtype containing the ␣6 subunit. This receptor subtype has high affinity for GABA and produces a degree of tonic inhibition on cerebellar granule cells, modulating the firing of these cells via spillover of GABA from GABAergic synapses. This receptor subtype also has selective affinity for the diuretic furosemide over receptors containing other ␣-subunits. Furosemide exhibits approximately 100-fold selectivity for ␣6-containing receptors over ␣1-containing receptors. By making ␣1/␣6 chimeras we have identified a transmembrane region (209 -279) responsible for the high furosemide sensitivity of ␣6␤3␥2s receptors. Within the ␣1 transmembrane region, a single amino acid was identified that when mutated from threonine to isoleucine, increased furosemide sensitivity by 20-fold. We demonstrate the ␤-subunit selectivity of furosemide to be due to asparagine 265 in the ␤2 and ␤3 transmembrane-domain II similar to that observed with potentiation by the anticonvulsant loreclezole. We also show that Ile in transmembrane-domain I accounts for the increased GABA sensitivity observed at ␣6␤3␥2s compared with ␣1␤3␥2s receptors, but did not affect direct activation by pentobarbital or potentiation by the benzodiazepine flunitrazepam. Location of these residues within transmembrane domains leads to speculation that they may be involved in the channel-gating mechanism conferring increased receptor activation by GABA, in addition to conferring furosemide sensitivity.
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In the mammalian brain, inhibitory neurotransmission is mainly mediated via activation of GABA A receptors, which belong to a superfamily of ligand-gated ion channels. The mammalian GABA A receptor gene family consists of a number of subunit polypeptides (␣ 1-6 , ␤ 1-3 , ␥ 1-2 , ␦, and ⑀) that are thought to coassemble as pentamers (Whiting et al., 1995; Sieghart, 1995) . Native GABA A receptor subtypes most likely consist of ␣ and ␤ subunits together with a ␥, ␦, or ⑀ subunit. The binding of GABA to the receptor complex results in the opening of an anion channel through which chloride ions flow. In addition to the GABA binding site, a number of allosteric sites have been identified on the receptor, which can modulate GABAergic activity. These include the benzodiazepines and anesthetics, which potentiate GABAergic responses, and antagonists such as picrotoxin and zinc, which act in a noncompetitive manner (Macdonald and Olsen, 1994) .
Another compound identified as a noncompetitive antagonist at GABA A receptors is the diuretic compound furosemide. This blocker of the Na ϩ /2Cl -/K ϩ cotransporter, has also been shown to be receptor subtype-selective, eliciting approximately 100-fold greater sensitivity for ␣6␤2␥2s receptors than for ␣1␤2␥2s receptors (Korpi et al., 1995) , as well as selectivity for ␣6␤3␥2s over ␣6␤1␥2s. The aim of this study was to identify the amino acids within the ␣6 subunit and ␤3 subunit that are responsible for conferring high affinity for this antagonist, using chimeric receptors and point mutations.
Materials and Methods
Cloning of human GABA A receptor subunit cDNAs (␣1-␣6, ␤3, and ␥2s) has been described previously (Hadingham et al., 1993a (Hadingham et al., ,b, 1996 Wafford et al., 1996) . Chimeric and point-mutated cDNAs were generated by standard techniques as described previously . Mutations were confirmed by DNA sequencing.
Expression of Human GABA A Receptors in Xenopus Oocytes. Adult female Xenopus laevis were anesthetized by immersion in a 0.4% solution of 3-aminobenzoic acid ethylester for 30 to 45 min (or until unresponsive). Ovary tissue was removed via a small abdominal incision and stage V and VI oocytes were isolated with fine forceps. After mild collagenase treatment to remove follicle cells (Type IA, 0.5 mg ml Ϫ1 for 6 min), the oocyte nuclei were directly injected with 10 to 20 nl of injection buffer (88 mM NaCl, 1 mM KCl, 15 mM HEPES, at pH 7, filtered through nitro-cellulose) containing different combinations of human GABA A subunit cDNAs (20 ng l Ϫ1 ) engineered into the expression vector pCDM8 or pcDNAI/Amp. After incubation for 24 to 72 h, oocytes were placed in a 50 l bath and perfused at 4 to 6 ml/min Ϫ1 with modified Barth's medium consisting of 88 mM NaCl, 1 mM KCl, 10 mM HEPES, 0.82 mM MgSO 4 , 0.33 mM Ca(NO 3 ) 2 , 0.91 mM CaCl 2 , 2.4 mM NaHCO 3 , at pH 7.5. Cells were impaled with two 1 to 3 M⍀ electrodes containing 2 M KCl and voltage-clamped at Ϫ70 mV.
In all experiments drugs were applied in the perfusate until the peak of the response was observed. Noncumulative concentrationresponse curves to GABA and pentobarbital were constructed with an interval of 3 min between each agonist application.
Inhibition curves to furosemide (0.3-3000 M) were constructed using a GABA EC 50 concentration. Furosemide was preapplied for 30 s before addition of the GABA EC 50 concentration and furosemide. The effects of flunitrazepam were examined on control GABA EC 20 responses with a preapplication time of 30 s. A minimum of two Xenopus toads were used for each data set.
Whole Cell Patch-Clamp of Human Embryonic Kidney (HEK) 293 Cells Transiently Transfected with Human GABA A Receptors. Experiments were performed on HEK 293 cells transiently transfected with human cDNA combinations ␣1␤3␥2s, ␣6␤3␥2s, ␣1T230I␤3␥2s, and ␣6I228T␤3␥2s (6 g of cDNA total per coverslip) using calcium phosphate precipitation (Chen and Okayama, 1988) as described previously (Hadingham et al., 1993a) . Glass coverslips containing the cells in a monolayer culture were transferred to a perspex chamber on the stage of Nikon Diaphot inverted microscope. Cells were continuously perfused with a solution containing 124 mM NaCl, 2 mM KCl, 2 mM CaCl 2 , 1 mM MgCl 2 , 1.25 mM KH 2 PO 4 , 25 mM NaHCO 3 , 11 mM D-glucose, at pH 7.2, and observed using phase-contrast optics. Patch-pipettes were pulled with an approximate tip diameter of 2 m and a resistance of 4 M⍀ with borosilicate glass and filled with 130 mM CsCl, 10 mM HEPES, 10 mM EGTA, 3 mM Mg ϩ -ATP, pH adjusted to 7.3 with CsOH. Cells were patch-clamped in whole-cell mode using an Axopatch-200B patch-clamp amplifier (Axon Inst., Foster City, CA). Drug solutions were applied by a double-barreled pipette assembly, controlled by a stepping motor attached to a Prior manipulator, enabling rapid equilibration around the cell. Increasing GABA concentrations were applied for 5-s pulses with a 30-s interval between applications.
Analysis. Curves were fitted using a nonlinear square-fitting program to the equation
n ] where x is the drug concentration, EC 50 is the concentration of drug eliciting a half-maximal response and n is the Hill coefficient. EC 50 and IC 50 values are shown as mean (95% CL), n ϭ 3 or more, and differences between means were evaluated by Student's t test and considered significant if P Ͻ .05.
Drugs Used. ␥-Aminobutyric acid (Sigma Chemical Co., St. Louis, MO) was prepared as a 1 M stock solution in modified Barth's medium. Concentrated stock solutions of furosemide (1 M) and flunitrazepam (10 mM) (both obtained from Sigma) were freshly prepared in 100% dimethyl sulfoxide. Pentobarbital was obtained from Rhône Mérieux (Harlow, UK) as a concentrate in alcohol (Sagatal for injection containing 60 mg ml Ϫ1 pentobarbitone sodium). The concentrates were diluted into buffer and the maximal final vehicle concentration was 0.3% v/v for dimethyl sulfoxide and 0.4% v/v for the alcohol. No effects on GABA currents were observed with either vehicle.
Results and Discussion
As has previously been reported (Korpi et al., 1995; Wafford et al., 1996) furosemide displays a greater sensitivity for (Fig. 1) . In addition, the ␥-subunit appears not to be required for furosemide antagonism, as ␣6␤3 receptors are also highly sensitive to block by furosemide, with an IC 50 of 14.4 (9.5, 21.9) M (data not shown).
A number of chimeras (C1-C5) were made encompassing different regions of the ␣1 and ␣6 subunits ( Fig. 2A) and expressed with human ␤3 and ␥2 subunits in Xenopus oocytes. Chimeras 1 and 3 both displayed ␣1-like furosemide sensitivity Fig. 3 . Alignment of human GABA A ␣1 and ␣6 subunits. Numbering is according to mature ␣1 polypeptide. The figure shows the four putative transmembrane domains and the two regions containing the amino acids responsible for the high sensitivity at ␣6-containing receptors identified from the ␣1/6 chimeras. Within the first region shaded in yellow (131-160) there are seven amino acid differences between ␣1 and ␣6 whereas the second region shaded in blue (209 -279) has 12. (Table 1a) . These results suggest that there are at least two amino acids responsible for the high furosemide sensitivity of ␣6-containing receptors, the first being located within a region between amino acids 131 and 160 and the second between 209 and 279 (Fig. 3) . Identification of Isoleucine228 in TransmembraneDomain (TM) 1. In the region between positions 209 and Fig. 5 . The sensitivity of furosemide is determined in part by the presence of isoleucine at position 228 within the ␣6 subunit. Representative current recordings illustrate the concentration-dependent inhibition by furosemide (0.3 M -3 mM) of the inward current evoked by an EC 50 concentration of GABA on Xenopus oocytes expressing ␣6␤3␥2s (A), ␣1␤3␥2s (B), and ␣1T230I␤3␥2s (C) receptors. Drug application is illustrated by the horizontal bars above the current records. 279 there are 12 amino acid differences between ␣1 and ␣6. Fisher et al. (1997) described a rat ␣6/␣1 chimera with a splice site within TM1 that conferred high furosemide sensitivity and a ␣1 point mutation (␣1L258T) where furosemide sensitivity was unchanged. These results eliminated 5 of the 12 amino acids identified within this region. The remaining seven amino acids were mutated (in groups of 2 or 3) in ␣1 to the ␣6 equivalent and the furosemide IC 50 determined.
␣1V212I (Fig. 4) , demonstrating a critical role for isoleucine 228 within the ␣6 subunit in conferring furosemide selectivity. Figure 5 illustrates the effects of furosemide on oocytes expressing wild-type ␣1␤3␥2s, ␣6␤3␥2s, and ␣1T230I␤3␥2s receptors. The effects of furosemide were shown to be significantly reduced on the equivalent ␣6 receptor mutant (␣6I228T), producing a 10-fold reduction in furosemide sensitivity with an IC 50 of 127.6 (86.3, 188.6) M (Fig. 6A) . In addition, when the same wild-type and equivalent mutants were expressed in HEK cells and studied using whole cellpatch-clamp techniques, similar differences were observed in furosemide sensitivity (Fig. 6B, Table 1b) .
Interestingly, the threonine residue is conserved in all other ␣-subunits, including the ␣4 subunit, that has intermediate furosemide sensitivity , and so cannot account for the higher affinity of ␣4-containing receptors for furosemide. Mutation of this conserved threonine to isoleucine in ␣4 produced a 10-fold increase in furosemide sensitivity with an IC 50 of 22.3 (18.5, 26.9) M, similar to ␣6␤3␥2s receptors. (Fig. 7) .
The location of this residue in TM1 suggests that TM1 may form part of the ion channel with the residue providing a binding site for furosemide. The residue may also have a role in ion-channel gating, possibly making the receptor more amenable to block by furosemide. Thus mutation of a single amino acid within the ␣1 subunit from threonine to the ␣6 equivalent isoleucine at position 230 produced a 20-fold increase in furosemide sensitivity. This single amino acid change, however, did not shift the IC 50 completely to that observed on ␣6␤3␥2 receptors, suggesting that other residues are also involved.
Additional Determinants Affecting Furosemide Sensitivity. Our results from the chimera studies identified a possible second domain (131-160) within the ␣6 subunit, which may contribute to the high furosemide sensitivity. Within the transmembrane domain of ␣1, a single amino acid changed to the ␣6 equivalent, ␣1T230I, increased the furosemide sensitivity of ␣1 by 20-fold. A further 5-fold increase in sensitivity is required to bring the furosemide IC 50 to that seen on ␣6␤3␥2s or chimera 2. Single amino acid mutations or insertion of the region 131 to 160 into ␣1 however, did not affect the furosemide IC 50 (see Table 1a , chimera 6), so it is currently unclear how this small additional component is conferred. The action of furosemide has also been shown to depend on the ␤-subunit variant, being weaker on ␤1-containing receptors than on ␤2-and ␤3-containing receptors (Korpi et al., 1995) . Potentiation of GABA A receptors by the anticonvulsant loreclezole has been shown to be dependent on the ␤-subunit and is dependent on the presence of asparagine 265 in the ␤2 or ␤3 subunit . We have compared the effects of furosemide on ␣6␤1␥2 and ␣6␤3␥2 receptors, confirming selectivity for ␣6␤3␥2. We have also used ␤ point mutants, ␤1S265N and ␤3N265S, coexpressed with ␣6 and ␥2s to demonstrate that the ␤-subunit selectivity is determined by the same asparagine residue as loreclezole (Fig. 8) . Mutation of the serine within ␤1 to asparagine (the ␤3 counterpart) increased furosemide sensitivity [from an IC 50 of 66.5 (63.3, 70.0) M to 12.3 (11.8, 12.9 ) M]. Conversely, mutation of the asparagine within ␤3 to serine decreased furosemide sensitivity [from an IC 50 of 12.4 (11.4, 12.9) M to 224 (190, 263) M]. It is interesting to note that mutation within the ␤1 subunit revealed an identical IC 50 as ␣6␤3␥2s whereas mutation within the ␤3 subunit produced a significantly higher IC 50 than ␣6␤1␥2s. Like the threonine/isoleucine we have identified in TM1, the asparagine/serine is located on the extracellular end of TM2 and it is possible that these two amino acids are located close to each other at the extracellular face of the channel.
Isoleucine 228 in ␣6 Also Confers Higher GABA Affinity. Interestingly, concentration-response curves for GABA expressing the wild-type ␣1␤3␥2, ␣6␤3␥2, and the corresponding Thr/Ile mutants revealed significant differences in GABA affinity. The GABA EC 50 for ␣1T230I␤3␥2s receptors [0.84 (0.77, 0.91 Hence, this mutation could also account for the higher GABA affinity of ␣6-containing receptors. GABA concentration-response curves in Xenopus oocytes were also carried out on the mutant ␣1 and ␣6 receptors, as well as all the ␣1/␣6 chimeras, however, the greater intrinsic variability in the oocyte expression system precluded the significant detection of such a 5-fold difference. The location in TM1 makes it unlikely that this residue forms part of the GABA binding site, which has been shown to be formed by residues in the ␣ and ␤-subunit N-terminal regions (Sigel et al., 1992; Amin and Weiss, 1993) . The EC 50 value is a function of both the GABA binding affinity and the isomerization rate constants for transitions between the various closed, open, and desensitized states. Channel gating involves conformational changes in the membrane-spanning domains and we hypothesize that mutation from threonine 230 to isoleucine within TM1 alters the transduction process, resulting in a lower EC 50 value. The high GABA affinity of ␣6-containing receptors has recently been shown to be critical to their function in granule cells, as mediating a tonic inhibition via spillover of GABA from Golgi to granule cell synapses (Brickley et al., 1996; Rossi and Hamann, 1998) .
Similar to GABA and furosemide, direct activation by pentobarbital displays ␣6 selectivity and was therefore examined on Xenopus oocytes expressing ␣1␤3␥2s and ␣1T230I␤3␥2s receptors. No differences were observed in either the EC 50 or maximum response as a percentage of the maximum GABA response (189 M and 75% for ␣1␤3␥2 compared with 191 M and 66% for ␣1T230I␤3␥2s). Additionally, potentiation of a GABA EC 20 by the benzodiazepine flunitrazepam (1 M) was unaffected by the threonine to isoleucine mutation (104 Ϯ 13% for ␣1␤3␥2s and 90 Ϯ 8% for ␣1T230I␤3␥2s). Although mutation of Thr230 to Ile within the ␣1 subunit significantly increased furosemide and GABA affinity, it did not alter the direct activation of pentobarbital or the potentiation elicited by flunitrazepam.
The role of the putative membrane spanning TM1 has also been investigated in the muscle nicotinic receptor (Akabas and Karlin, 1995) using cysteine substitution experiments. They suggest that the top third (N terminal) of TM1 contributes to the lining of the ion channel and hypothesize that in the closed state, TM1 segments intercalate between TM2 at the extracellular end. On receptor activation, movements of TM1 and TM2 could flip a gate, possibly formed by the cytoplasmic loop between them. If the same is true in the homologous GABA A receptor, by interacting directly with TM1, furosemide could be stabilizing this closed state of the ion channel gate. The position of the asparagine in ␤2 and ␤3, however, is hypothesized to be facing away from the lumen of the channel (Xu and Akabas, 1996) ; if this is the case, it may interact with the residues identified within TM1 in this study. Further study of the effects of this mutation at the single channel level will enhance our understanding of how this residue affects channel function and the mechanism of furosemide antagonism.
